Clinical and Applied Thrombosis/Hemostasis (Dec 2021)

Clinical Features of Disseminated Intravascular Coagulation According to the French-American-British Classification in Patients With Acute Leukemia and Thrombomodulin Alfa Treatment—A Cohort Study Using a Postmarketing Surveillance Database

  • Seki Yoshinobu MD, PhD,
  • Goichi Honda PhD,
  • Noriaki Kawano MD, PhD,
  • Toshimasa Uchiyama MD, PhD,
  • Kazuo Kawasugi MD, PhD,
  • Seiji Madoiwa MD, PhD,
  • Naoki Takezako MD, PhD,
  • Ikezoe Takayuki MD, PhD,
  • Hideo Wada MD, PhD

DOI
https://doi.org/10.1177/10760296211054094
Journal volume & issue
Vol. 27

Abstract

Read online

The aims of this study were to analyze the clinical features of a large number of cases with disseminated intravascular coagulation (DIC) associated with acute leukemia and to assess the safety and efficacy of thrombomodulin alfa (TM-α) using the French-American-British (FAB) classification of hematological malignancies. We retrospectively examined 644 patients with acute leukemia in postmarketing surveillance for TM-α. M3, M2, M4, M1, and M5 subtypes of acute myeloid leukemia (AML) and L2 and L1 subtypes of acute lymphoblastic leukemia (ALL) have been found more frequently among patients with DIC. Bleeding symptoms at baseline were more frequent in M3 and M7 subtypes. Fibrinogen concentrations were lower, and plasmin-plasmin inhibitor complex values were higher in M3 and Philadelphia-positive (Ph+) ALL. Overall DIC resolution rate was 60.2%, higher in L1 and Ph+ ALL, lower in M1, and generally higher in ALL than in AML. Overall survival rate was generally high, at 79.8%, with higher rates in L3, Ph+ ALL, and M3. Regardless of FAB subgroup, TM-α showed improved bleeding symptoms and DIC scores in clinical practice for DIC patients with acute leukemia.